The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis

Inclusion Criteria: 1. .Males and non-pregnant females and aged ≥ 18 years with chronic kidney disease not on dialysis; 2. .Willing and able to adhere to visit schedules and all study requirements; 3. .Subjects read and signed the study-specific informed consent. 4. .Subjects who has either received the first dose of 2013-2014 seasonal influenza vaccination before or not. Exclusion Criteria: 1. .Subject or his/her family is employed by the participated hospital; 2. .History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication; 3. .Personal or family history of Guillain-Barré Syndrome; 4. .An acute febrile illness within 1 week prior to vaccination; 5. .Current upper respiratory illness, including the common cold or nasal congestion within 72 hours; 6. .Subjects with influenza-like illness as defined by the presence of fever (temperature ≥ 38°C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough; 7. .Female subjects who are pregnant during the study. 8. .Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent; 9. .Immunodeficiency, or under immunosuppressive treatment. 10. .Receipt of any vaccine within 1 week prior to study vaccination or expected receipt between Visit 1 (study vaccination) and Visit 2 (final collection of blood samples); 11. .Receipt of any blood products, including immunoglobulin in the prior 3 months; 12. .Any severe illness needed to be hospitalization within three months. 13. .Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine.